Nobutaka Nakamura

1.0k total citations
19 papers, 862 citations indexed

About

Nobutaka Nakamura is a scholar working on Clinical Biochemistry, Nephrology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Nobutaka Nakamura has authored 19 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Clinical Biochemistry, 8 papers in Nephrology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Nobutaka Nakamura's work include Advanced Glycation End Products research (14 papers), Chronic Kidney Disease and Diabetes (8 papers) and Natural Antidiabetic Agents Studies (4 papers). Nobutaka Nakamura is often cited by papers focused on Advanced Glycation End Products research (14 papers), Chronic Kidney Disease and Diabetes (8 papers) and Natural Antidiabetic Agents Studies (4 papers). Nobutaka Nakamura collaborates with scholars based in Japan and United States. Nobutaka Nakamura's co-authors include Takanori Matsui, Sho‐ichi Yamagishi, Ayako Ojima, Yoshinori Nishino, Yuichiro Higashimoto, Kuniyoshi Kaseda, Kei Fukami, Yuri Nishino, Yuji Ishibashi and Seiya Okuda and has published in prestigious journals such as Diabetes, International Journal of Molecular Sciences and Diabetic Medicine.

In The Last Decade

Nobutaka Nakamura

19 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nobutaka Nakamura Japan 14 398 363 197 155 153 19 862
Yuri Nishino Japan 16 441 1.1× 343 0.9× 202 1.0× 162 1.0× 131 0.9× 28 912
Ayako Ojima Japan 15 401 1.0× 271 0.7× 241 1.2× 104 0.7× 138 0.9× 18 771
Felicia Y. T. Yap Australia 12 495 1.2× 369 1.0× 209 1.1× 135 0.9× 266 1.7× 15 1.0k
Hiromi Fujishima Japan 12 389 1.0× 152 0.4× 260 1.3× 258 1.7× 206 1.3× 12 1.0k
Motofumi Sasaki Japan 13 334 0.8× 104 0.3× 202 1.0× 177 1.1× 177 1.2× 16 781
Josefa Pete Australia 7 197 0.5× 351 1.0× 329 1.7× 186 1.2× 82 0.5× 9 891
Keiichiro Matoba Japan 18 337 0.8× 154 0.4× 480 2.4× 385 2.5× 166 1.1× 41 1.2k
Maki Murakoshi Japan 18 223 0.6× 145 0.4× 218 1.1× 369 2.4× 109 0.7× 55 905
Kohachiro Koga Japan 9 292 0.7× 571 1.6× 217 1.1× 174 1.1× 48 0.3× 11 943
Dhruv K. Singh United Kingdom 11 158 0.4× 115 0.3× 202 1.0× 287 1.9× 104 0.7× 19 798

Countries citing papers authored by Nobutaka Nakamura

Since Specialization
Citations

This map shows the geographic impact of Nobutaka Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobutaka Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobutaka Nakamura more than expected).

Fields of papers citing papers by Nobutaka Nakamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobutaka Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobutaka Nakamura. The network helps show where Nobutaka Nakamura may publish in the future.

Co-authorship network of co-authors of Nobutaka Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Nobutaka Nakamura. A scholar is included among the top collaborators of Nobutaka Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobutaka Nakamura. Nobutaka Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Nakamura, Nobutaka, et al.. (2020). Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction. International Journal of Molecular Sciences. 21(7). 2604–2604. 5 indexed citations
3.
Nakamura, Nobutaka, et al.. (2019). Long-Term Local Injection of RAGE-Aptamer Suppresses the Growth of Malignant Melanoma in Nude Mice. Journal of Oncology. 2019. 1–10. 11 indexed citations
4.
Kaifu, Kumiko, Seiji Ueda, Nobutaka Nakamura, et al.. (2018). Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4. Microvascular Research. 120. 90–93. 23 indexed citations
5.
Hosono, Makoto, Hideharu Ikebuchi, Yoshihide Nakamura, et al.. (2018). Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Annals of Nuclear Medicine. 32(3). 217–235. 38 indexed citations
6.
Matsui, Takanori, Yuichiro Higashimoto, Yuri Nishino, et al.. (2017). RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy. Diabetes. 66(6). 1683–1695. 105 indexed citations
7.
Ishibashi, Yuji, et al.. (2017). Methylglyoxal-derived hydroimidazolone-1 evokes inflammatory reactions in endothelial cells via an interaction with receptor for advanced glycation end products. Diabetes and Vascular Disease Research. 14(5). 450–453. 24 indexed citations
8.
Matsui, Takanori, Nobutaka Nakamura, Ayako Ojima, Yoshinori Nishino, & Sho‐ichi Yamagishi. (2016). Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta. Nutrition Metabolism and Cardiovascular Diseases. 26(9). 797–807. 60 indexed citations
9.
Yamagishi, Sho‐ichi, Nobutaka Nakamura, & Takanori Matsui. (2016). Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. Journal of Diabetes. 9(2). 141–148. 73 indexed citations
10.
Ojima, Ayako, Takanori Matsui, Yoshinori Nishino, Nobutaka Nakamura, & Sho‐ichi Yamagishi. (2015). Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Hormone and Metabolic Research. 47(9). 686–692. 183 indexed citations
11.
Yamagishi, Sho‐ichi, et al.. (2015). Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Molecular Medicine. 21(S1). S32–S40. 136 indexed citations
12.
Matsui, Takanori, Yuri Nishino, Ayako Ojima, et al.. (2015). Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Laboratory Investigation. 95(5). 525–533. 45 indexed citations
13.
Nakamura, Nobutaka, Takanori Matsui, Yuji Ishibashi, & Sho‐ichi Yamagishi. (2015). Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetology & Metabolic Syndrome. 7(1). 48–48. 60 indexed citations
14.
Ushigome, Emi, Michiaki Fukui, Masahide Hamaguchi, et al.. (2014). Factors affecting variability in home blood pressure in patients with type 2 diabetes: post hoc analysis of a cross-sectional multicenter study. Journal of Human Hypertension. 28(10). 594–599. 13 indexed citations
15.
Ojima, Ayako, Takanori Matsui, Nobutaka Nakamura, et al.. (2014). DNA Aptamer Raised Against Advanced Glycation End Products (AGEs) Improves Glycemic Control and Decreases Adipocyte Size in Fructose-Fed Rats by Suppressing AGE-RAGE Axis. Hormone and Metabolic Research. 47(4). 253–258. 21 indexed citations
16.
Hasegawa, Goji, Hiroshi Obayashi, Takahiro Kanatsuna, et al.. (2003). The Association Between End-Stage Diabetic Nephropathy and Methylenetetrahydrofolate Reductase Genotype with Macroangiopathy in Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. 111(3). 132–138. 17 indexed citations
17.
Yamaguchi, Masamitsu, Nobutaka Nakamura, Yoshihiro Kitagawa, et al.. (1998). Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy. Diabetic Medicine. 15(6). 458–462. 40 indexed citations
18.
Nakamura, Nobutaka, Yasuhide Kitagawa, Go Hasegawa, et al.. (1998). Advanced Glycation End Products Induce Expression of Vascular Endothelial Growth Factor by Retinal Müller Cells.. Retina. 18(5). 491–491. 4 indexed citations
19.
Tsurumi, Hisashi, Takanori Yamada, Masumi Sawada, et al.. (1995). [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].. PubMed. 36(7). 657–64. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuri Nishino Breakdown of academic impact, for papers by Ayako Ojima Breakdown of academic impact, for papers by Felicia Y. T. Yap Breakdown of academic impact, for papers by Hiromi Fujishima Breakdown of academic impact, for papers by Motofumi Sasaki Breakdown of academic impact, for papers by Josefa Pete Breakdown of academic impact, for papers by Keiichiro Matoba Breakdown of academic impact, for papers by Maki Murakoshi Breakdown of academic impact, for papers by Kohachiro Koga Breakdown of academic impact, for papers by Dhruv K. Singh
Rankless by CCL
2026